The EBMT/EHA CAR-T Cell Handbook

The first open-access European CAR-T Handbook, co-promoted by the EBMT and EHA, covers CAR-T cell treatments, underlying biology, indications, side-effects management, access, and manufacturing issues. It is written by leading experts to enhance readers' knowledge and practice skills.

Format: Paperback / softback
Length: 237 pages
Publication date: 08 February 2022
Publisher: Springer Nature Switzerland AG

This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers' knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care.

The CAR-T cell therapy is a revolutionary treatment for blood cancers that involves engineering patients' T cells to produce chimeric antigen receptors (CARs) that specifically target cancer cells. CAR-T cells are harvested from the patient's blood, engineered in a laboratory, and then infused back into the patient. The CARs on the T cells recognize and bind to specific proteins on the surface of cancer cells, triggering the cells to destroy themselves.

One of the key advantages of CAR-T cell therapy is its high efficacy in treating blood cancers that have previously been difficult to treat. CAR-T cells can target multiple types of cancer cells and can produce long-lasting responses in patients. However, the treatment also comes with risks and side effects, including cytokine release syndrome (CRS), neurotoxicity, and immune-related adverse events (IRAEs).

The CAR-T Handbook provides a comprehensive overview of the CAR-T cell therapy process, from the initial diagnosis and screening of patients to the infusion of the engineered cells and the management of side effects. It covers the underlying biology of CAR-T cells, including their development, manufacture, and characterization. It also discusses the indications for CAR-T cell therapy, including the types of blood cancers that can be treated and the criteria for patient selection.

The Handbook provides detailed information on the management of side effects, including the use of steroids, immunosuppressants, and other medications to control CRS and IRAEs. It also discusses the importance of monitoring patients during and after treatment and the role of supportive care in improving outcomes.

Access to CAR-T cell therapy is a significant challenge for many patients, particularly those in low- and middle-income countries. The Handbook discusses the issues surrounding access and manufacturing, including the need for regulatory approval, the cost of treatment, and the availability of resources and infrastructure. It also highlights the efforts of organizations and governments to improve access to CAR-T cell therapy and the potential for partnerships and collaborations to achieve this goal.

In conclusion, the CAR-T Handbook is a valuable resource for healthcare professionals and researchers interested in the field of CAR-T cell therapy. It provides a comprehensive overview of the technology, its application in clinical care, and the challenges and opportunities associated with this innovative treatment. By enhancing readers' knowledge and practice skills, the Handbook
This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers' knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care.

The CAR-T cell therapy is a revolutionary treatment for blood cancers that involves engineering patients' T cells to produce chimeric antigen receptors (CARs) that specifically target cancer cells. CAR-T cells are harvested from the patient's blood, engineered in a laboratory, and then infused back into the patient. The CARs on the T cells recognize and bind to specific proteins on the surface of cancer cells, triggering the cells to destroy themselves.

One of the key advantages of CAR-T cell therapy is its high efficacy in treating blood cancers that have previously been difficult to treat. CAR-T cells can target multiple types of cancer cells and can produce long-lasting responses in patients. However, the treatment also comes with risks and side effects, including cytokine release syndrome (CRS), neurotoxicity, and immune-related adverse events (IRAEs).

The CAR-T Handbook provides a comprehensive overview of the CAR-T cell therapy process, from the initial diagnosis and screening of patients to the infusion of the engineered cells and the management of side effects. It covers the underlying biology of CAR-T cells, including their development, manufacture, and characterization. It also discusses the indications for CAR-T cell therapy, including the types of blood cancers that can be treated and the criteria for patient selection.

The Handbook provides detailed information on the management of side effects, including the use of steroids, immunosuppressants, and other medications to control CRS and IRAEs. It also discusses the importance of monitoring patients during and after treatment and the role of supportive care in improving outcomes.

Access to CAR-T cell therapy is a significant challenge for many patients, particularly those in low- and middle-income countries. The Handbook discusses the issues surrounding access and manufacturing, including the need for regulatory approval, the cost of treatment, and the availability of resources and infrastructure. It also highlights the efforts of organizations and governments to improve access to CAR-T cell therapy and the potential for partnerships and collaborations to achieve this goal.

In conclusion, the CAR-T Handbook is a valuable resource for healthcare professionals and researchers interested in the field of CAR-T cell therapy. It provides a comprehensive overview of the technology, its application in clinical care, and the challenges and opportunities associated with this innovative treatment. By enhancing readers' knowledge and practice skills, the Handbook

The CAR-T cell therapy is a revolutionary treatment for blood cancers that involves engineering patients' T cells to produce chimeric antigen receptors (CARs) that specifically target cancer cells. CAR-T cells are harvested from the patient's blood, engineered in a laboratory, and then infused back into the patient. The CARs on the T cells recognize and bind to specific proteins on the surface of cancer cells, triggering the cells to destroy themselves.

One of the key advantages of CAR-T cell therapy is its high efficacy in treating blood cancers that have previously been difficult to treat. CAR-T cells can target multiple types of cancer cells and can produce long-lasting responses in patients. However, the treatment also comes with risks and side effects, including cytokine release syndrome (CRS), neurotoxicity, and immune-related adverse events (IRAEs).

The CAR-T Handbook provides a comprehensive overview of the CAR-T cell therapy process, from the initial diagnosis and screening of patients to the infusion of the engineered cells and the management of side effects. It covers the underlying biology of CAR-T cells, including their development, manufacture, and characterization. It also discusses the indications for CAR-T cell therapy, including the types of blood cancers that can be treated and the criteria for patient selection.

The Handbook provides detailed information on the management of side effects, including the use of steroids, immunosuppressants, and other medications to control CRS and IRAEs. It also discusses the importance of monitoring patients during and after treatment and the role of supportive care in improving outcomes.

Access to CAR-T cell therapy is a significant challenge for many patients, particularly those in low- and middle-income countries. The Handbook discusses the issues surrounding access and manufacturing, including the need for regulatory approval, the cost of treatment, and the availability of resources and infrastructure. It also highlights the efforts of organizations and governments to improve access to CAR-T cell therapy and the potential for partnerships and collaborations to achieve this goal.

In conclusion, the CAR-T Handbook is a valuable resource for healthcare professionals and researchers interested in the field of CAR-T cell therapy. It provides a comprehensive overview of the technology, its application in clinical care, and the challenges and opportunities associated with this innovative treatment. By enhancing readers' knowledge and practice skills, the

Weight: 471g
Dimension: 235 x 155 (mm)
ISBN-13: 9783030943523
Edition number: 1st ed. 2022